色素障碍性皮肤病

980954 晕痣和痣细胞痣OKT_6阳性细胞的免疫组化观察/普雄明（新疆维吾尔自治区人民医院皮肤科）…//中国皮肤性病学杂志.-1997,11（5）.-272 着重对晕痣（8例）和痣细胞痣（8例）进行了3OKT_6标记的免疫组织化学的观察。结果表明痣细胞痣表皮内OKT_6阳性细胞较少,而且大多数细胞轮廓清楚,树状突明显,真皮浅层及痣细胞巢内未见到阳性细胞。晕痣表皮内OKT_6阳性细胞明显多于痣细胞痣。少数阳性细胞树突小而少,轮廓不清,特点是晕痣的真皮浅层及痣细胞巢内也可见到少数阳性细胞,晕痣绝大多数由痣细胞痣发展而来,认为其发生与自身免疫有关。LC晕痣损害内明显多于痣细胞痣,提示它可能     

晕痣和痣细胞痣的免疫组化比较观察

应用ＩｇＧ、ＩｇＤ、ＩｇＭ和Ｃ３ｃ４种标记抗体对１１例晕痣和１３例痣细胞痣进行了平行免疫组化观察，结果显示晕痣与痣细胞痣具有明显不同的免疫病理特点，支持晕痣的发生与自身免疫有关的观点。     

277例晕痣的临床回顾性分析

目的:总结晕痣的临床特点,初步探讨晕痣与白癜风的临床相关性。方法:对277例晕痣患者的临床特点进行分析,并对部分患者进行随访。结果:277例行晕痣切除术的患者中,皮损单发219例(79.06%),多发58例(20.94%)。好发于面颈部(54.86%)与躯干(37.03%)。106例患者(38.27%)并发白癜风,其平均发病年龄小于未并发白癜风者(P=0.041)。随访110例未并发白癜风的晕痣患者术后转归,17例继发白癜风,其中11例于半年内发生。比较未并发白癜风的晕痣患者与继发白癜风的晕痣患者,后者多发晕痣的比例高于前者(P=0.003)。结论:晕痣皮损以单发多见,面颈部好发。晕痣发病年龄小、皮损多发是白癜风发病的危险因素。手术切除是治疗晕痣的一种有效方法,晕痣切除术后半年可能是白癜风发生的高风险期,应密切随访。     

先天性色素痣术后诱发白癜风及多发性晕痣一例

先天性色痣（Congenital Pigmented Nevus）是一种特殊类型的痣细胞痣,约有10%的恶变倾向[1]。临床上为预防恶性变,常切除巨大色素痣。现将1例患者先天性色痣切除后诱发白癜风及多发性晕痣报告如下。     

31例晕痣的临床分析及光电镜观察

本文对31例晕痣的临床资料进行了分析,并作了7例光镜和4例电镜观察.结果表明:31例晕痣患者中伴发白癜风14例(45.1%).晕痣痣细胞周围有密集的淋巴细胞浸润.痣细胞有受损,最后则消失.晕痣的皮肤内郎格罕细胞增多.晕部表皮中黑素细胞消失.结果提示:晕痣的组织学特征符合免疫学改变.此外,本文实验还观察到晕痣组织中一种较为特殊的细胞,推测可能是郎格罕细胞在皮肤内行有丝分裂.     

晕痣和痣细胞痣OKT6阳性细胞的免疫组化观察

对晕痣和痣细胞痣进行了 OKT6阳性细胞的免疫组化观察 ,结果表明晕痣表皮内 OKT6阳性细胞数显著多于痣细胞痣 ,提示 OKT6阳性细胞可能在晕痣的自身免疫发病机制中起着一定作用     

晕痣和痣细胞痣主要组织相容复合体（MHC）抗原的免疫组化观察

应用免疫组化方法观察了晕痣和痣细胞痣组织内主要组织相容复合体（ＭＨＣ）抗原的表达，结果ＭＨＣⅡ类抗原在两种痣组织内表达明显不同，作者认为痣细胞ＭＨＣⅡ类抗原的过量表达可能与晕痣发生的自身免疫机制有关。     

晕痣和痣细胞痣bcl-2蛋白的表达

为了研究细胞凋亡在晕痣发生中的作用,我们对8例晕痣和8例痣细胞痣患者皮损进行了bcl-2原癌基因产物(B-cell lymphoma/leukemia 2 gene product,以下简称bcl-2)的免疫组化观察.结果表明8例晕痣均见有bcl-2的阳性表达,8例痣细胞痣仅有3例表达bcl-2,而且染色明显较弱,大部分组织呈阴性表达.由于两种痣bcl-2表达明显不同,作者认为晕痣组织内bcl-2的过量表达与晕痣发生的自身免疫机制有关,可能是痣组织内对痣细胞的高凋亡率的一种自动平衡反应.     

晕痣80例临床分析

目的:了解晕痣的临床特征。方法:对80例晕痣患者(共92个晕痣)进行回顾性临床分析。结果:患者的平均年龄(18±3)岁,2例患者有家族史,62例并发白癜风,69例患者只发生1个晕痣。在92个晕痣中,躯干部62个,其中背部32个;痣周围色素脱失斑呈椭圆形的58个,呈圆形的32个;痣表面皮肤色素有脱失的35个。28个晕痣切除后行皮肤组织病理检查,其中交界痣3例,混合痣4例,皮内痣21例。结论:大部分晕痣与白癜风并发;躯干是好发部位;多呈椭圆形;组织病理上多为皮内痣。     

晕痣的免疫组化特点与自发性消退机制的研究

目的 研究晕痣自发性消退早期及晚期皮损区炎细胞表型、数目及其分布特点，探讨晕痣自发性消退的免疫机制。方法 应用免疫组化方法对晕痣皮损区、非皮损区及正常对照皮肤进行CD3、CD4、CD8、CD20、CD1a、CD56、CD68染色，用计算机图像分析系统（Image-pro PLUS 6.0）观察及定量分析。结果 晕痣早期及晚期皮损区CD4、CD8、CD20、CD1a阳性细胞数均明显高于非皮损区及正常对照皮肤（P ＜ 0.01），皮损区CD1a、CD68阳性细胞直径明显大于非皮损区及正常对照皮肤（P ＜ 0.01）。消退晚期CD8 与CD4阳性细胞数目比值（2.05 ∶ 1）高于消退早期（1.82 ∶ 1），CD8阳性细胞在痣细胞巢内大量浸润。结论 CD4、CD8、CD20、CD1a、CD56、CD68阳性细胞均参与晕痣自发性消退，CD8阳性T细胞在晕痣消退中起主要作用。     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Multiple New-Onset Subcutaneous Nodules of the Upper Extremity Digits: Giant Cell Tumor of Tendon Sheath and Lipoma

A black woman with the concurrent onset of two subcutaneous nodules located on the digits of her upper extremities is described. Initially, a single systemic disorder was considered; yet, the lesions differed in morphology and consistency. Microscopic examination of the nodules showed a giant cell tumor of tendon sheath and a lipoma. Although Occam's “razor” suggests that multiple lesions in the same person are more likely to represent variable manifestations of a single disorder than several different diseases in that individual, the simultaneously appearing lesions in this patient represented two different conditions.     

Deutliche Einschränkung der Lebensqualität bei Patienten mit Pemphigus vulgaris: Ergebnisse der deutschen Bullous Skin Disease (BSD)‐Studiengruppe

Background: Pemphigus vulgaris is a potentially life‐threatening autoimmune disorder of the skin and mucous membranes characterized by antibodies against epidermal adhesion molecules. Clinically characteristic are painful chronic blisters or erosions of mucous membranes and skin. There are no published studies on the impact o this disease on quality of life. Patients and methods: This registration was performed within the scope of the German BSD (Bullous Skin Disease) study group, from November 1997 until January 2002. A total of 36 patients with the first diagnosis of pemphigus vulgaris were registered at the university hospitals of Dresden, Erlangen, Kiel, Mannheim, München and Würzburg. Thirty of the 36 (83 %) patients participated in the quality of life questionnaire utilizing the German version of ‘Dermatology Life Quality Index’ (DLQI) provided by A. Y. Finlay. The DLQI varies from 0 to 30 with an increased DLQI score indicating a decrease in quality of quality. Results: The overall DLQI total score of 10 ± 6,7 in the investigated pemphigus patients was significantly increased in comparison to other skin diseases. Conclusions: These results suggest that the DLQI can be a very useful additional outcome criteria for clinical studies with pemphigus vulgaris and in the treatment of these patients.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Medición del impacto psicológico en pacientes con psoriasis en tratamiento sistémico

Background and objectives

The negative impact of psoriasis on patient quality of life can be as important as the physical consequences of the disease. We could assume that clearance of the disease would also lead to an improvement in its psychosocial impact. The present study assesses the psychological state of patients with psoriasis receiving systemic treatment in a psoriasis unit, especially those with mild or no disease involvement.